Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in AdultsGlobeNewsWire • 05/21/24
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)GlobeNewsWire • 05/16/24
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week ConferenceGlobeNewsWire • 05/07/24
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewsWire • 05/02/24
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical MeetingsGlobeNewsWire • 05/01/24
Ardelyx (ARDX) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 04/25/24
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and StrategyGlobeNewsWire • 03/25/24
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 02/22/24
Ardelyx (ARDX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 02/15/24